SCHEMBL12058

SCHEMBL12058

CC[C@]1(O)CC[C@@]2(CCN(c3ccc(OCC(F)(F)F)cc3)C2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 9/20 0.42
EPHX2 P34913 2/20 0.40
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
ACACB O00763 1/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
CACNA2D1 P54289 1/20 0.36
CACNA2D2 Q9NY47 1/20 0.36
MCHR1 Q99705 1/20 0.34
MEN1 O00255 2/20 0.34
USP2 O75604 2/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
KMT2A Q03164 2/20 0.34
MAPK1 P28482 1/20 0.34
CYP2C19 P33261 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578 0.82 LIPE (0.34) LIPEITGB3ITGA2BCTSBCTSS
SCHEMBL5614 0.77 LIPE (0.60) LIPEEPHX2CTSBCTSSCTSK
SCHEMBL1590028 0.75 LIPE (0.64) LIPE
SCHEMBL4918 0.75 LIPE (0.64) LIPE
SCHEMBL4917 0.75 LIPE (0.64) LIPE
SCHEMBL4962 0.74 RYR2 (0.41) LIPEITGB3ITGA2BACACBMEN1
SCHEMBL5485 0.72 RYR2 (0.45) ITGB3ITGA2BMEN1USP2ALDH1A1
SCHEMBL5019 0.72 SLC6A4 (0.49) LIPEEPHX2
SCHEMBL5680 0.71 CYP3A4 (0.43) MEN1USP2ALDH1A1CYP3A4CYP2C9
SCHEMBL5287 0.70 CHRM4 (0.44) LIPEEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488493-A1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES F. Hoffmann-La Roche AG (CH) 2012-08-22 EP disclosed
WO-2011045292-A1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2011-04-21 WO disclosed